OTC: CADMF

Chemesis International Inc.

COMPANY PROFILE:

Chemesis International Inc. (CSE: CSI / OTC: CADMF) is an innovative leader in the cannabis industry. With a worldwide reach and exclusive partnerships, Chemesis establishes and grows new markets around the globe.

Chemesis provides knowledge, structure and confident leadership to increase revenues through Cultivation, Manufacturing and Distribution to Retail. With current operations underway in Puerto Rico with Natural Ventures and in California with California Sap, Chemesis expects rapid growth in the emerging fully licensed and fully compliant cannabis industry.

Things That Investors Know About This IPO That Drove a 402% Share Value Boom in Just 2 Months.

YOUNG INVESTORS LOVE CANNABIS STOCKS!

Companies like Chemesis (CSE: CSI / OTC: CADMF) are the preferred stock play by investors aged between 22 and 37.

Investors born between 1981 and 1996 – the “millennials” – account for about 75% the cannabis-related securities trades over the past months, according to data from TD Ameritrade.

This crowd also trades more actively — about 25% more than other groups.

Below are the 7 REASONS WHY Investors Love Chemesis (CSE: CSI / OTC: CADMF)

1

THE PUBLIC SUPPORTS LEGALIZING ADULT-USE CANNABIS PRODUCTS

To begin with, the American public is very much in support of seeing cannabis legalized.

Five separate polls(1) over the past year from the well-known and well-respected news outlets like Gallup, Fox News, CBS News, Pew Research Center, and the independent Quinnipiac University, found support for legalization among adults ranging from 59% to 64%.

By comparison, just 25% of respondents approved of legalization back in Gallup’s survey in 1995.

This shows just how quickly the perception of cannabis has changed in just more than 20 years.

Chemesis (CSE: CSI / OTC: CADMF) understands that factor is driving the cannabis investor market.

Chemesis sees the wave, and has plans in place to ride it for the long-term.

2

AND IT OVERWHELMINGLY IS IN FAVOR OF LEGALIZING MEDICAL CANNABIS

Support for legal access to medical cannabis is even higher.

A survey from Quinnipiac University in April 2018 found that 93% of those surveyed supported the idea of patients having access to medical cannabis products prescribed by a physician.

That compares to just 5% who opposed the idea of legal medical marijuana.

Again, Chemesis (CSE: CSI / OTC: CADMF) realizes this growing trend, and works carefully with medical labs and researchers in California to develop products and delivery systems that an eager consumer market will be able to access in the near future.

3

29 U.S. STATES HAVE BROAD-SWEEPING MEDICAL CANNABIS LAWS

Within the U.S., a sort of bifurcated system exists that’s thus far allowed states the ability to legalize and regulate recreational and/or medical marijuana independently of the federal government.

Since 1996, when California became the first state to legalize medical marijuana for compassionate-use patients, 29 states in total have passed broad-sweeping medical pot laws. Source(2)

That is why Chemesis (CSE: CSI / OTC: CADMF) has operational facilities based in California (as well as farm and processing facilities in Puerto Rico.)

Chemesis understands that California is the “growth center” of this exploding industry in the US, and may create a working model for more jurisdictional expansion.

Chemesis (CSE: CSI) / OTC: CADMF keeps a focused perspective on the increasing size – both numerically and regionally – of the cannabis marketplace, and plans growth to meet that demand.

4

NINE STATES ALLOW ADULTS TO USE RECREATIONAL CANNABIS

Additionally, nine states have OK’d the use of recreational marijuana since November 2012.

The latest to do so is Vermont, which gave the green light(3) to recreational weed entirely through the legislative process in January 2018. (In Vermont, residents voted directly on the issue. Residents in the other eight states approved their cannabis initiative by voting it into state law.)

As this list grows, Chemesis (CSE: CSI / OTC: CADMF) sees a clear path for revenue growth and the resulting opportunity for investors to possibly reap great rewards.

5

THE FDA MAY BE ON THE VERGE OF ITS FIRST CANNABINOID-BASED DRUG APPROVAL

The Food and Drug Administration (FDA) appears to be less than two months away from giving the thumbs up to the very first drug derived from compounds found in the cannabis plant (known as cannabinoids).

One company is working on a cannabis-centered drug designed to treat two rare forms of childhood-onset epilepsy.

Early tests(4) showed a statistically significant reduction in seizure frequency, relative to baseline and when compared to the placebo, in multiple late-stage studies.

The drug was recommended for approval by the FDA’s advisory panel in April.

History could be around the corner, with an FDA decision date currently set for later this year.

Chemesis (CSE: CSI / OTC: CADMF) again recognizes this new frontier in both medicine and cannabis-charged drugs. And that forward-looking vision is another factor investors love about Chemesis.

6

CANADA LEGALIZED RECREATIONAL MARIJUANA USE

The U.S. could very well become the most lucrative marijuana market on the planet. But when retail cannabis becomes legal in October, that title goes to Canada.

Our northern neighbor now has legalized recreational marijuana for adults. It is now the first developed country in the world to do so.

And the Canadian market may signal the opening of the floodgates around the world for more legalized pot.

That is why Chemesis (CSE: CSI / OTC: CADMF) has specific plans in place for operational expansion throughout Europe, South America and into Oceania.

And investors like a company – like Chemesis – with global vision. That is another reason the stock rose 402% in just 2 months!

7

OILS AND EXTRACTS ARE A HIGHER-MARGIN PRODUCT

PRODUCT DIFFERENTIATION IS IMPORTANT FOR MARIJUANA STOCKS.

Moving beyond highly commoditized dried cannabis products is critical to success.

In particular, companies like Chemesis (CSE: CSI / OTC: CADMF) that retail cannabis oils and extracts, stand to generate juicier margins than those that don’t.

Oils and extracts have a significantly higher price point and target niche consumers.

They’re the secret sauce to increasing margins.

CHEMESIS’ NETWORK OF COMPANIES DELIVERS WHAT CONSUMERS WANT

BELOW ARE THE TRIO OF COMPANIES WHICH FORM THE CORE OF THE CHEMESIS (CSE: CSI / OTC: CADMF) RECIPE OF CONSUMER SUCCESS.

Natural Ventures is the operations headquarters located in Puerto Rico.

It holds strategic partnerships with an expanding number of leading brands in the cannabis industry spanning across multiple countries.

SAP Global is a state-of-the-art production facility strategically located in Cathedral City, California.

The facility is able to produce high quality legally compliant cannabis products for distribution in California.

The headquarters of Desert Zen Distribution & Transport is in the Coachella Valley.

All California cannabis distribution needs are under one roof.

All of this leads to what consumers want: great products at easy-to-reach retail outlets.

Chemesis (CSE: CSI / OTC: CADMF) products are industry leaders because of their cutting-edge extraction and processing techniques, and the use of 100% organically grown cannabis.

NATURAL VENTURES PRODUCTS INCLUDE:

  • Cannabis-infused Peanut Butter Cups with 88.41 mg THC per serving
  • CannaCaps THC & MCT Oil with 10.18 mg THC
  • THC and Hemp Oil in Mango, Mint, Raw, Lavender and Guava flavours, each with 24.61 mg THC
  • Ananda Cannabis Infused Lotion (2 oz.) with 58.92 mg THC
  • White Chocolate Strawberry Jam with 100 mg THC

SAP GLOBAL OFFERS THESE PRODUCTS UNDER THE LABEL “CALIFORNIA SAP.”

  • GRAMQUL is the favorite vape pen with the highest award-winning CO2 Sap. For dabbing and favourite recipes
  • High quality cannabis-oil filled vape cartridges, featuring a unique Airflow Control Valve.

HERE ARE THE

3 BIG

REASONS CONSUMERS LOVE CHEMESIS

1. CULTIVATION

It starts with a state-of-the-art grow facility in Puerto Rico.

The operation includes a 2,000+ grow light capacity and a 30,000+ lb overall grow capacity.

Additionally, Chemesis (CSE: CSI / OTC: CADMF) has multiple expansion opportunities currently under review in both Puerto Rico and California.

2. MANUFACTURING

Chemesis (CSE: CSI / OTC: CADMF) offers its clients a wide variety of cannabis-based extractions, formulations & products.

They specialize in BHO Extraction, Alcohol Extraction, and CO2 Extraction and currently have the capacity to process more than 2,000 lbs of raw material per day

3. DISTRIBUTION

Chemesis (CSE: CSI / OTC: CADMF) is in harmony with distributors around the world.

With new regulations affecting the California market, Chemesis (CSE: CSI / OTC: CADMF) will emerge as a fully compliant industry leader.

In the Puerto Rico market, Chemesis has an established presence serving the entire island from seed to sale.

If you are eager to jump on the cannabis investment train, Chemesis (CSE: CSI / OTC: CADMF) is the penny stock you should explore.

(1, 2, 3) Fool.com
(4) Arcview

KEY DATA
KEY EXECUTIVES

CEO & DIRECTOR - EDGAR MONTERO

PRESIDENT & DIRECTOR - AMANDEEP SINGH PARMAR

LOCATION

VANCOUVER, BC - CANADA

SECTOR

DIVERSIFIED INDUSTRY

INDUSTRY

CONSUMER GOODS

ADDITIONAL STOCK SYMBOLS

CSE: - CSI

FRA: - CWAA

NAME*

GREEN STOCK REPORT RESPECTS YOUR PRIVACY.

SUBSCRIBE & GET THE LATEST CHEMESIS STOCK ALERTS

SUBSCRIBE & GET THE LATEST CHEMESIS STOCK ALERTS